Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR3F1P
|
|||
| Drug Name |
BNT112
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 2 | [1] | |
| Company |
BioNTech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04382898) First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.